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Abstract
Witteveen-Kolk syndrome (OMIM 613406) is a recently defined neurodevelopmental syndrome caused by heterozygous
loss-of-function variants in SIN3A. We define the clinical and neurodevelopmental phenotypes related to SIN3A-
haploinsufficiency in 28 unreported patients. Patients with SIN3A variants adversely affecting protein function have mild
intellectual disability, growth and feeding difficulties. Involvement of a multidisciplinary team including a geneticist,
paediatrician and neurologist should be considered in managing these patients. Patients described here were identified
through a combination of clinical evaluation and gene matching strategies (GeneMatcher and Decipher). All patients
consented to participate in this study. Mean age of this cohort was 8.2 years (17 males, 11 females). Out of 16 patients ≥ 8
years old assessed, eight (50%) had mild intellectual disability (ID), four had moderate ID (22%), and one had severe ID
(6%). Four (25%) did not have any cognitive impairment. Other neurological symptoms such as seizures (4/28) and
hypotonia (12/28) were common. Behaviour problems were reported in a minority. In patients ≥2 years, three were
diagnosed with Autism Spectrum Disorder (ASD) and four with Attention Deficit Hyperactivity Disorder (ADHD). We
report 27 novel variants and one previously reported variant. 24 were truncating variants; three were missense variants and
one large in-frame gain including exons 10–12.
Introduction
Witteveen-Kolk syndrome (OMIM #613406) was first
described in 2016 with characteristic distinctive facial fea-
tures, microcephaly, short stature, mild intellectual dis-
ability (ID) with delayed cognitive and motor development
and subtle anomalies on MRI-brain imaging [1]. Although
sparsely reported, frameshift as well as missense variants in
the Switch-insensitive 3 transcription regulator family
member A (SIN3A) (OMIM *607776) have been described
in larger neurodevelopmental disorder cohorts, with an
overall mild clinical picture [2]. Narumi-Kishimoto et al.
presented a further patient with SIN3A frameshift variant
and facial features of Witteveen-Kolk with relatively mild
ID and normal growth [3].
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The SIN3A gene is located in the chromosome 15 band
q24 and is within the shortest region of overlap of various
reported 15q24 microdeletions, therefore, is thought to be
the critical gene for the atypical 15q24 microdeletion syn-
drome [4]. SIN3A encodes a transcriptional regulatory
protein, which is associated with scaffolding in the core
histone deacetylase complex [5]. In our earlier study, we
showed that SIN3A is involved in cortical neurogenesis,
supporting the hypothesis that variants in the gene that
adversely affect its function lead to a broad range of
developmental and neurological problems. We identified an
additional 28 patients with SIN3A variants in order to
comprehensively define the phenotype with a focus on both
developmental and behavioural aspects, as well as investi-
gating genotype-phenotype correlations.
Methods
We collected the molecular and clinical features on 28
unpublished individuals with SIN3A variants by a colla-
boration facilitated by Deciphering Developmental Dis-
orders (DDD study) [6], GeneMatcher [7] and DECIPHER
(DECIPHER v9.24: https://decipher.sanger.ac.uk/) [8], in
which, several clinical groups independently identified
individuals with developmental delay/intellectual disability
(DD/ID) and related phenotypes with rare variants in SIN3A
during routine diagnostic genetic testing. An application to
the DDD study for a Complementary Analysis Project was
made, allowing access to anonymised details of patients
with SIN3A variants identified through this study
(https://www.ddduk.org/). Clinicians of selected patients
were then contacted to invite patients and their families to
be recruited. Clinical analysis of these patients was per-
formed during regular consultations focusing on medical
history, physical examination and observational analysis of
behavioural features along with reported history by the
family. In all patients, exome sequencing and variant fil-
tering were performed, according to the routine protocol
and diagnostic procedures at each institute.
Identified patients with a class 4 or 5 variants (likely
pathogenic or pathogenic variants) in SIN3A, according to
the American College of Medical Genetics (ACMG) cri-
teria, were approached to participate in this study. Informed
consent for publication was obtained from all patients and/
or their guardians. The responsible clinician reviewed
medical records of each participant in order to compre-
hensively document the phenotype.
The clinical significance of the variants identified was
interpreted according to the ACMG [9] guidelines and
further review publications [10]. Excluded from the study
were: patients with an additional proven genetic diagnosis
where the SIN3A variant was not thought to be contributory
or the sole pathogenic finding, those with a chromosomal
anomaly explaining or likely to be explaining the pheno-
type, and those in whom SIN3A variants were of uncertain
clinical significance with no convincing clinical correlation.
All the variants reported here have been submitted to
DECIPHER database [https://decipher.sanger.ac.uk] and
phenotypes are included in DECIPHER database for the




In this study, we reported 28 patients with variants that
adversely affect protein function and which are classified as
pathogenic or likely pathogenic variants in SIN3A. The
findings of this study expand the variant spectrum pre-
viously reported in SIN3A,3. 27/28 patients in this study
have novel variants. Patient 15 with c.3310C>T, p.
(Arg1104*) variant is a family member of a patient we have
previously reported in Witteveen et al. [1]. Predominantly,
variants found in our patient cohort are truncating and
predicted to result in a protein loss-of-function (25/28). All
24 truncating variants have been classified as variants that
adversely affect function (pathogenic) using the ACMG and
ACGS (The Association for Clinical Genomics Science)
variant classification guidelines using criterions: PVS1,
PM2, and PS2 where appropriate [9, 10]. Of the four
remaining variants, three were missense (patients 4, 18 and
26; Table 1) and one was a large in-frame gain which
included the whole of exons 10, 11 and 12 (patient 24;
Table 1). These four variants were all de novo in our
patients with a specific and consistent phenotype to SIN3A
and were absent from control population data sets in gno-
mAD (https://gnomad.broadinstitute.org/). We have also
used criterion PM1 at moderate level for two of the three
reported missense variants, c.377C>T, p.(Ala126Val) and
c.463A>G, p.(Lys155Glu), as they were located within a
protein functional domain. These results show that missense
causative variants are not clustered in a hot spot within
SIN3A (Fig. 1 provides a schematic SIN3A structure and
variant locations which, as demonstrated, are distributed
throughout the gene). Details of the variants, ACMG cri-
terions and classification are listed in Table 1.
Assessment of pathogenicity of missense variants in
SIN3A
In order to assess if missense variants in our cohort were
predicted to adversely affect the critical functional domains
in SIN3A, we used a 3D model based on the solution
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Table 1 Variant Table.
No Variant using NM_001145358.1 Inheritance ACMG criterion Classification Published DECIPHER ID
1 c.1462del; p.(Val488Leufs*7) De novo PS2-T/PVS1/PM2-M Pathogenic Novel 278680
2 c.2764C>T; p.(Arg922*) De novo PS2-T/PVS1/PM2-M Pathogenic Novel 306260
3 c.588del; p.(Asn197Metfs*4) De novo PS2-T/PVS1/PM2-M Pathogenic Novel 271952
4 c.377C>T; p.(Ala126Val) De novo PS2-T/PM1-M/PM2-M/PP3-S Likely Pathogenic Novel 262798
5 c.1245_1246del; p.(Asn415Lysfs*24) De novo PS2-T/PVS1/PM2-M Pathogenic Novel 293976
6 c.775dup; p.(His259Profs*47) De novo PS2-T/PVS1/PM2-M Pathogenic Novel 263709
7 c.824del; p.(Pro275Hisfs*12) De novo PS2-T/PVS1/PM2-M Pathogenic Novel 307508
8 c.2248_2251del; p.(Leu750Metfs*43) De novo PS2-T/PVS1/PM2-M Pathogenic Novel 266515
9 c.2339del; p.(Ala780Glyfs*14) De novo PS2-T/PVS1/PM2-M Pathogenic Novel 260388
10 c.889C>T; p.(Gln297*) De novo PS2-T/PVS1/PM2-M Pathogenic Novel 264582
11 c.1715_1722delinsCCCAAGTGTA; p.(Gly572Alafs*11) De novo PS2-T/PVS1/PM2-M Pathogenic Novel 292229
12 c.3323C>G; p.(Ser1108*) De novo PS2-T/PVS1/PM2-M Pathogenic Novel 282105
13 c.3490A>T; p.(Lys1164*) De novo PS2-T/PVS1/PM2-M Pathogenic Novel 282212
14 c.46C>T; p.(Gln16*) Maternal PVS1/PM2-M Pathogenic Novel 421224
15 c.3310C>T; p.(Arg1104*) Unknown PVS1/PM2-M Pathogenic Witteveen et al. [1] 421225
16 c.2809_2810del; p.(Lys937Glufs*2) De novo PS2-T/PVS1/PM2-M Pathogenic Novel 421226
17 c.1489_1499del; p.(Arg497Cysfs*13) De novo PS2-T/PVS1/PM2-M Pathogenic Novel 421228
18 c.3317T>C; p.(Met1106Thr) De novo PS2-T/PM2-M/BP4-S Likely Pathogenic Novel 421229
19 c.1675C>T; p.(Arg559*) De novo PS2-T/PVS1/PM2-M Pathogenic Novel 421230
20 c.3303C>G; p.(Tyr1101*) De novo PS2-T/PVS1/PM2-M Pathogenic Novel 421231
21 c.1570_1577del; p.(Tyr524Valfs*26) De novo PS2-T/PVS1/PM2-M Pathogenic Novel 421232
22 c.2185_2186del; p.(Leu729Glyfs*8) De novo PS2-T/PVS1/PM2-M Pathogenic Novel 421233
23 c.3441_3445del; p.(Lys1148Argfs*12) De novo PS-2-T/PVS1/PM2-M Pathogenic Novel 421234
24 c.1318_1737dup; p.(Val580Lysfs*35) De novo PS2-T/PVS1 Pathogenic Novel 421236
25 c.1773G>A; p.(Trp591*) De novo PS2-T/PVS1/PM2-M Pathogenic Novel 421237
26 c.463A>G; p.(Lys155Glu) De novo PS2-T/PM1-M/PM2-M/PP3-S Likely Pathogenic Novel 421238
27 c.2803C>T; p.(Arg935*) De novo PS-2T/PVS1/PM2-M Pathogenic Novel 421239
28 c.1888dup; p.(Ile630Asnfs*17) De novo PS-2/PVS1/PM2-M Pathogenic Novel 421240
ACMG Criterion applied:
PS2-T: De novo (both maternity and paternity confirmed) in a patient with the disease and no family history, used at strong level.
PVS1: null variant (nonsense, frameshift, canonical ±1 or 2 splice sites, initiation codon, single or multiexon deletion) in a gene where LOF is a known mechanism of disease.
PM1-M: Located in a critical functional domain without benign variation, used at moderate level.
PM2-M: Absent from controls in gnomAD database, used at moderate level.
PP3-S: Multiple lines of computational evidence support a deleterious effect on the gene or gene product, used at supporting level.
PM4-M: Protein length changes as a result of in-frame deletions/insertions in a non-repeat region or stop-loss variants, used at moderate level.
BP4-S: Multiple lines of computational evidence suggest no impact on gene or gene product, used at supporting level
No corresponds to patient number.












































structure of mouse SIN3A PAH1 bound to the Sin3 inter-
action domain (SID) of SAP25 (SIN3A Associated Protein
25) [11]. The pair of amphipathic helices (PAH) domains
are predicted as important for the recruitment by and
interaction with a diverse number of transcription factors
and therefore, critical for protein function [12, 13]. Both
altered residues by c.377C>T, p.(Ala126Val) and
c.463A>G, p.(Lys155Glu) were predicted to be part of the
SAP25 SID-binding surface. We predicted that SIN3A
Ala126 with its small hydrophobic side chain formed a
pocket for the larger hydrophobic side chain of SAP25
Leu142 and was invariant across species [11].
SIN3A Lys155 is also predicted to form a 2.2A hydrogen
bond with the polar Gln143 of SAP25 (orange line in Fig. 2)
and was also conserved in the PAH1 domain across species.
Along with the lack of normal variation in this region (using
missense constraint data in SIN3A from Decipher: https://
decipher.sanger.ac.uk/gene/SIN3A#overview/protein-info), we
applied criterion PM1 at moderate level for the classification of
both c.377C>T, p.(Ala126Val) and c.463A>G, p.(Lys155-
Glu). We also suggest that PM1 can be applied at a moderate
level for missense variants within residues p.119–189 of the
SIN3A protein providing that the change caused by the variant
was not present in other species and also meets the PM2
criteria (see Fig. 2).
Finally, the c.3317T>C, p.(Met1106Thr) is within the C-
terminal domain of SIN3A, this region is not well char-
acterised and the in silico pathogenicity prediction programs
suggests a benign effect (REVEL score of 0.105 shows a
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Fig. 1 Characteristic facial appearance of patients with variants in
SIN3A. Note the high forehead, small, pointed chin and down-slanting
palpebral fissures. A: Patient 1, B Patient 2, C Patient 4, D Patient 5, E
Patient 9, F Patient 11, G Patient 12, H Patient 13, I Patient 16,
J Patient 18, K Patient 25, L Patient 27, M Patient 28.
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de novo in patient 18, novel in control populations in
gnomAD and with a consistent phenotype to that of the rest
of our cohort. No other variants were found in this patient
on exome sequencing. Therefore, we classified this variant
in addition as likely pathogenic, but without the use
of PM1.
Clinical findings
Table 2 shows a summary of the characteristics of 28
patients (17 males, 11 females) with variants in SIN3A who
were included in this retrospective study. The mean age of
participants was 8.2 years (range 0.6–67 years). Table 3
provides an overview of salient features described in this
cohort in comparison to published literature and Table 4 has
detailed phenotypic information on this cohort of patients.
Development
Of 28 patients, 15 (56%) had global developmental delay.
Out of 16 patients ≥8 years old, (one patient was not for-
mally assessed) seven (44%) had mild intellectual disability
(ID), four had moderate ID (25%), and one had severe ID
(6%). Four (25%) did not appear to have any cognitive
impairment. In 21 patients ≥5 years old, some form of motor
developmental delay was reported in 13 patients (62%) and
in 16 patients (76%) there was some form of language
developmental delay. Intelligence Quotient (IQ) was only
formally measured in 6/28 patients and the score ranged
from 60 to 100. This suggests that patients within this
cohort have low normal intelligence.
Autism spectrum disorder (ASD) is rarely diagnosed
before the age of 24 months [14]. In one patient aged
14 months, ASD was thought possible but not formally
assessed due to the young age. In three of 23 patients ≥2
years (13%), ASD was diagnosed. Attention Deficit
Hyperactivity Disorder (ADHD) is most commonly diag-
nosed in children between 6 and 12 years, though this can
be diagnosed in a younger age group. ADHD was diag-
nosed in four patients ≥2 years (17%).
Growth and feeding difficulties
13/28 (46%) patients in our cohort had head circumference
at least two standard deviations (SD) below the mean.
Weight was less than two SD below the mean in 8/28
patients (29%) and height was less than two SD below the
mean in 5/28 patients (18%).15/28 (54%) of patients had
feeding difficulties with at least two patients documented to
require nasogastric tube feeding mainly in the neonatal
period.
Craniofacial features
Fourteen (50%) patients were reported to have craniofacial
dysmorphism. In ten patients, the facial gestalt was
Fig. 2 Schematic SIN3A protein structure and variant location. ITD: intragenic deletion; Plot of variants done using St. Jude Cloud protein
paint (https://pecan.stjude.cloud/proteinpaint).
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Table 2 Select phenotypic characteristics of SIN3A cohort compared with previously published literature.













2 DECIPHER 306260 M/1.2 y c.2764C>T, p.(Arg922*) Language-and
motor delay
?ASD Hypotonia?; epilepsy










3 DECIPHER 271952 F/8.3 y c.588del, p.(Asn197Metfs*4) Mild ID, language-
and motor delay
ADHD Hypotonia Yes No







Neonatal hypotonia Yes No Constipation; sacral
dimple, Hirsute on back
as baby; pes planus joint
hypermobility hearing
impairment (mixed)
5 DECIPHER 293976 M/10.1 y c.1245_1246del, p.(Asn415Lysfs*24) Moderate ID,
language and
motor delay
None Neonatal hypotonia Yes OFC <−2SD Pectus excavatum.
Unilateral inguinal hernia;
Sacral dimple
6 DECIPHER 263709 M/5.4 y c.775dup, p.(His259Profs*47) GDD,
language delay












7 DECIPHER 307508 M/0.6 y c.824del, p.(Pro275Hisfs*12) GDD,
language delay






8 DECIPHER 266515 M/7.2 y c.2248_2251del, p.(Leu750Metfs*43) GDD, language-and
motor delay
None Hypotonia Yes Weight <
−2SD
OFC <−2SD
9 DECIPHER 260388 M/5 y c.2339del, p.(Ala780Glyfs*14) GDD language and
motor delay








10 DECIPHER 264582 M/3.2 y c.889C>T, p.(Gln297*) GDD, language-and
motor delay
















Febrile seizures No No








13 DECIPHER 282212 M/9.1 c.3490A>T, p.(Lys1164*) Mild ID,
language delay

















14 DECIPHER 421224 M/25 y c.46C>T, p.(Gln16*) Moderate ID, GDD,
language-and
motor delay
None Epilepsy, thinning of
the corpus callosum
No No
15 DECIPHER 421225 F/67 y c.3310C>T,p.(Arg1104*) Not formally
assessed, possible
mild ID





16 DECIPHER 421226 M/11.1 y c.2809_2810del,p.(Lys937Glufs*2) Mild ID, GDD,
language-
motor delay
None None No OFC < -2SD Scoliosis; Burkitt
lymphoma (at 8 y)
17 DECIPHER 421228 F/8.1 y c.1489_1499del, p.(Arg497Cysfs*13) Mild ID,GDD,
language-
motor delay







18 DECIPHER 421229 M/36.2 y c.3317T>C,p.(Met1106Thr) Moderate ID,
language-
motor delay
None Epilepsy No No
19 DECIPHER 421230 M/22.1 y c.1675C>T,p.(Arg559*) Mild ID ASD, depression,
psychosis
Sleeping problems Yes No Thickened aortic valve
20 DECIPHER 421231 F/24.2 y c.3303C>G,p.(Tyr1101*) Language delay Multiple Complex DD,
anxiety disorder
Hypotonia Yes No
21 DECIPHER 421232 F/19 y c.1570_1577del, p.(Tyr524Valfs*26) Normal Schizoaffective
disorder




22 DECIPHER 421233 M/10 y c.2185_2186del, p.(Leu729Glyfs*8) Mild motor delay None Hypotonia, epilepsy Unknown No
23 DECIPHER 421234 F/0.6 y c.3441_3445del,p.(Lys1148Argfs*12) Mild motor delay N/A Hypotonia Yes No
24 DECIPHER 421236 M/1.5 y c.1318_1737dup; p.(Val580Lysfs*35) GDD N/A Hypotonia, epilepsy Yes Unknown























No No Joint laxity, recurrent
otitis media; asthma;
scoliosis
28 DECIPHER 421240 F/6.5 y c.1888dup, p.(Ile630Asnfs*17) Mild GDD,?mild ID None Hypotonia No OFC <−2SD Joint laxity;
Unilateral hypermetropia;
multiple dental caries
Witteveen et al. [1]


















































confirmed independently by two clinical geneticists with
expertise in dysmorphology. Common facial features
included a broad, tall forehead; small mouth, thin upper lip
with pointed chin and down-slanting palpebral fissures (see
Fig. 3). The facial gestalt appears to be similar and poten-
tially recognisable but only in the context of reverse phe-
notyping with published images, confirming previous
findings. Three patients had a palatal defect with one also
having a bifid uvula.
Other clinical manifestations
In terms of neuroimaging, given the milder developmental
delay phenotype, many patients in the cohort have not had
MRI-brain imaging (19/28, 68%). Nine out of a total of nine
patients that had brain imaging performed had reports
available and in 7/9 (78%) abnormalities were seen. Most
common was ventriculomegaly in 2/9, and a hypoplastic/
dysplastic corpus callosum in 2/9. Cerebellar atrophy was
reported in two patients and there was one patient had a
Chiari 1 malformation.
6/28 (21%) patients were noted to have seizures currently
or in their past medical history. Hypotonia was a common
manifestation as well, present in 12/28 (43%) patients.
Other reported features included hearing loss (5/28;
18%) of which 1 patient had sensorineural hearing loss, two
patients had conductive hearing loss and two patients had
mixed hearing loss. Ocular abnormalities reported included
strabismus (1), nystagmus secondary to ocular albinism (1),
bilateral iris and chorioretinal coloboma (1) and
hypermetropia (1).
Of note, 2/28 patients were reported to have a malig-
nancy, including sigmoid adenocarcinoma in the 67-year
old patient which may be an age-related cancer and 1



















































































































































































































































































































































































































































































































































































































































































Table 3 Summary of salient features in SIN3A-related disorder based














16 7 1 24
Mild 8 5 – 13
Moderate 7 2 1 10
Severe 1 – – 1
Speech delay 11 2 1 13
Hypotonia 12 2 – 14
Feeding
difficulties
15 N/R – 15
Short stature 6 2 – 8
Epilepsy 4 1 – 5
Behavioural
problems
12 4 1 17
N/R not reported, overlap between mild-moderate ID reported as mild.
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eight). Patient 26 was noted to have T-cell lymphopenia at
age 11 associated with immunoglobulin deficiency and
significant bronchiectasis.
Discussion
Heterozygous loss-of-function variants in SIN3A were
recently described to result in a novel neurodevelopmental
syndrome comprising intellectual disability and varying
degrees of developmental delay. This syndrome defined as
Witteveen-Kolk syndrome was further characterised by
subtle brain abnormalities, including corpus callosum dys-
genesis and ventriculomegaly, distinctive facial features (a
broad, tall forehead; small mouth, thin upper lip with
pointed chin and down-slanting palpebral fissures), hyper-
laxity and short stature. Furthermore, we showed previously
that in vivo functional knockdown of SIN3A leads to
reduced cortical neurogenesis, altered neuronal identity and
aberrant cortico-cortical projections in the developing
mouse brain. Therefore, it is likely that the aberrant cortical
development underlies impaired neurodevelopment and
leads to cognitive and behavioural problems in patients,
varying from paediatric to adult-onset. Here, we summarise
the neurodevelopmental and facial phenotype in an addi-
tional 28 patients with SIN3A-related disorder.
Table 2 provides an overview of the patients reported
here and all previously reported patients with SIN3A
structural variants alone. Supplementary table provides a
comprehensive review of all the clinical information avail-
able on this cohort. Below is extracted information from
these tables.
Genotype-phenotype correlation in SIN3A
Most of the patients in this cohort (25/28; 89%) have
truncating or frameshift variants in SIN3A except three
patients with missense variants (Patients 4, 18 and 26)
which have been classed as a class 4 (likely pathogenic)
variant based on a combination of evidence as previously
described (see variant table for further information). It is
likely that as previously described haploinsufficiency is the
predominant likely mechanism in SIN3A-related disorder
but it may be that the phenotype may differ depending on
the nature of the SIN3A variant. From the evidence gathered
so far, there is no apparent correlation between severity of
phenotype and genotype.
Neurodevelopment
As noted in our earlier study [1], the overall intellectual dis-
ability seems to be mild, with 11 of the 16 patients (69%) over
the age of eight years having either no ID or mild ID. The low
prevalence of severe intellectual disability different from the
neurodevelopmental phenotype of moderate or severe intel-
lectual disability associated with 15q24 microdeletion syn-
drome, suggests that additional genes contribute to the
cognitive phenotype in the 15q24 deletion syndrome [15].
The median intelligence is relatively high with IQ of 74.
Interestingly, all patients in whom intelligence was tested
reported a higher verbal than performal intelligence score.
This is an important finding that clinicians should be aware of,
since disharmonic intelligence profiles easily lead to over-
estimating of the self-management capabilities of patients. A
further study is planned to undertake detailed psychometric
assessments and IQ measurements in this cohort.
Behavioural phenotype
Overall, a third of the cohort had a psychiatric or beha-
vioural condition reported, including ADHD, aggressive
behaviour, OCD, depression, psychosis, anxiety and schi-
zoaffective disorder. In three patients, ASD was concurrent
with a psychiatric diagnosis. This is a significant finding,
since such neuropathology has a significant impact on the
quality of life of patients especially in those adults with
milder neurodevelopmental phenotypes. Knowing that
Fig. 3 3D model to demonstrate predicted consequences of SIN3A
missense variant in our cohort. This 3D-model is based on the
solution structure of mouse Sin3A PAH1 bound to the Sin3 interaction
domain (SID) of SAP25 (Sin3A Associated Protein 25) displayed
using UCSF Chimera v1.14 (Pattersen et al. 2004). The PAH1 domain
of Sin3A (residues 119-189; sphere model, light grey) with residues
Ala126 (red) and Lys155 (blue) highlighted. The SAP25 protein SID
domain (residues 126-186; ball and stick model, dark grey) binds in
the fold formed by the four helices of Sin3A PAH1. Sin3A Lys155 is
predicted to form a 2.2A hydrogen bond with the polar side chain of
Gln143 of SAP25 (orange line).
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patients with variants in the SIN3A gene are at risk for such
concerns, early intervention is important to ensure optimal
treatment and outcomes.
Of those patients with psychiatric disease, only two had
brain imaging done. Interestingly, both those MRIs showed
ventriculomegaly, while one also showed delayed myeli-
nation. The younger patients in the cohort did not have any
neuroimaging done given the milder clinical presentation.
However, it is likely that once the diagnosis of a SIN3A-
related disorder is made, imaging of the brain should be
offered in the context of neurological symptoms rather than
routine work-up.
Craniofacial dysmorphism
Our previous study presented evidence for a characteristic
facial appearance associated with SIN3A. Some of the
patients in this cohort have clear similarities. As with many
of the mild and variable neurodevelopmental phenotypes, it
remains to be seen whether the facial gestalt is easily
identifiable in clinical practice. However, there appears to
be a common, emerging facial phenotype with a tall, broad
forehead, down-slanting palpebral fissures, triangular face
with a pointed chin and a thin upper lip, based on the
patient’s photographs (both included and unpublished but
shared with the authors due to parental consent for pub-
lication of photos being declined).
Interestingly, one patient was first suspected of progeria,
because of the typical shape of his neurocranium (Patient
25: J). Following genetic testing, he was diagnosed with a
variant in SIN3A, demonstrating that this may be part of the
spectrum of the syndrome. Patient 12: G also appears to
have a progeric face. Sparse hair and reduced subcutaneous
tissue was reported in 3/28 (10%) of patients in this study
and note the progeric appearance in at least two of the
patients in this cohort. However, no other ectodermal fea-
tures were identified. This leads to the possibility of dif-
ferential diagnoses including progeroid group of conditions;
however, SIN3A-related disorder does not appear to present
predominantly with a progeroid phenotype from the large
cohort described here.
Other clinical manifestations
14/28 (50%) patients in our study population had either
epilepsy, hypotonia, or both. Two out of the three patients
with epilepsy who had a brain MRI (of a total of five
patients with epilepsy) had abnormalities found. None of
the patients with epilepsy from this cohort reported any
psychiatric disease.
Interestingly, other commonly reported symptoms in
patients with intellectual disability were not reported in our
patient population. Constipation for instance, was only
reported in one patient, while hearing loss and refraction
abnormalities were also not as prevalent as in other intel-
lectual disability cohorts or the 15q24 microdeletion syn-
drome [15, 16].
Further information also needs to be collected to ascer-
tain whether malignancy is a significant association or
merely an observation with a large cohort of patients with
Witteveen–Kolk Syndrome. In addition, as described above,
additional features appear to be emerging from the larger
cohort of patients published here and further follow-up is
required to see if this is a consistent part of the phenotype.
Conclusion
Patients with disease causing variants in SIN3A usually
have mild global developmental delay/ID, with some even
having tested IQs in the normal range with variable pene-
trance. There are similar facial features in around half of
patients for which a targeted molecular evaluation would be
feasible. However, it is likely that diagnostic evaluation and
identification of SIN3A variants in suspected individuals
will be performed using large ID panels or WES/WGS.
There is evidence to suggest these patients are at risk for
psychiatric- and neurological conditions and therefore, a
multidisciplinary team approach should be considered in
caring for these patients. Data collected so far seems to
suggest additional features such as hypotonia, seizures
along with the previously well described neurodevelop-
mental association with this disorder.
There is no apparent genotype–phenotype correlation
and/ or missense variant hot spot within SIN3A and the
missense variants appear to be distributed throughout the
gene based on observation of this cohort. As expected,
majority of patients in published literature and this cohort
appear to have truncating variants reinforcing hap-
loinsufficiency as likely mechanism of pathogenicity,
although SIN3A missense variants affecting critical func-
tional domain in SIN3A also appear to be associated with
disease. Further studies of this nature are required to
ascertain clinical correlation in this disorder.
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